Drug-eluting stent thrombosis

Minerva Cardioangiologica

Volumn 56, Issue 1, 2008, Pages 127-137

  Steinberg, D H ^a,b   Satler, L F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Coronary restenosis; Drug eluting stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MORBIDITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; INCIDENCE; RISK FACTORS;

EID: 42049087177     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. George BS, Voorhees WD 3rd, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135-43.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
6. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C et al. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. N Engl J Med 2007;356:998-1008.
7. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
8. Camenzind E. Safety of Drug Eluting Stents: A Meta-analysis of First Generation DES programs World Congress of Cardiology. Barcelona, Spain, 2006.
9. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-814.
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ. van Es GA et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
11. Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of dnig-eluting stents. N Engl J Med 2007;356:1020-9.
12. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv 2007;69:1064-74.
13. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
14. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41.
15. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
16. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of dmg-eluting stents. Jama 2005;293:2126-30.
17. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv 2007;69:334-40.
18. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
19. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. Jama 2007;297:159-68.
20. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9.
21. Gurbel PA, DiChiara J, Tantry LIS. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol 2007;100:18M-25M.
22. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T et al. Aspirin and Clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
23. Gurbel PA, Bilden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-6.
24. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
25. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005;45:1753-6.
26. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.
27. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-7.
28. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7.
29. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
30. Chu WW, Waksman R. Contemporary Use of Drug-eluting Stents. Curr Treat Options Cardiovasc Med 2005;7:35-46.
31. Hodgson JM, Stone GW, Michael Lincoff A, Klein L, Walpole H, Bottner R et al. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent task force. Catheter Cardiovasc Interv 2007;69:327-33.
32. Tanabe K, Hoye A, Lemos PA, Aoki J, Arampatzis CA, Saia F et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 2004;94:115-8.
33. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-5.
34. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-94.
35. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66:507-11.
36. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
37. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005;45:351-6.
38. Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005;111:1383-9.
39. Holmes DR, Jr., Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. Jama 2006;295:1264-73.
40. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13.
41. Mishra S, Wolfram RM, Torguson R, Chu WW, Xue Z, Gevorkian N et al. Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis. Am J Cardiol 2006;97:1303-7.
42. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104.
43. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. Jama 2006;295:1253-63.
44. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005;46:613-20.
45. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
46. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006;47:205-7.
47. Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for onand off-label indications. Am J Cardiol 2007;100:1619-24.
48. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. Jama 2007;297:2001-9.
49. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
50. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
51. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
52. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007;28:961-7.
53. van Beusekom HM, Saia F, Zindler JD, Lemos PA, Swager-Ten Hoor SL, van Leeuwen MA et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007;28:974-9.
54. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
55. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
56. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44:1373-85.
57. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
58. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
59. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-7.
60. de Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998;19:1214-23.
61. de Ribamar Costa J, Jr., Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K et al. Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts. Am J Cardiol 2005;96:74-8.
62. de Ribamar Costa J, Jr., Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M et al. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J 2007;153:297-303.
63. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004;43:1959-63.
64. Cheneau E, Satler LF, Escolar E, Suddath WO, Kent KM, Weissman NJ et al. Underexpansion of sirolimus-eluting stents: incidence and relationship to delivery pressure. Catheter Cardiovasc Interv 2005;65:222-6.
65. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 2005;111:900-5.
66. Feres F, Costa JR, Jr., Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 2006;68:83-8.
67. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-9.
68. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-34.
69. Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 2007;28:1304-9.
70. Hong MK, Mintz GS, Lee CW, Park DW, Lee SW, Kim YH et al. Impact of late drug-eluting stent malapposition on 3-year clinical events. J Am Coll Cardiol 2007;50:1515-6.
71. Nakamura S, Colombo A, Gaglione A, Almagor Y, Goldberg SL, Maiello L et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994;89:2026-34.
72. Roy P, Torguson R, Okabe T, Pinto Slottow TL, Steinberg DH, Smith K et al. Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. J Interv Cardiol 2007;20:307-13.
73. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
74. Heller LI, Shemwell KC, Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 2001;53:23-8.
75. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005;26:1180-7.
76. Meier P, Zbinden R, Togni M, Wenaweser P, Windecker S, Meier B et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007;49:15-20.
77. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-4.
78. Steinberg DH, Pinto Slottow TL, Buch AN, Javaid A, Roy PK, Garg S et al. Impact of in-stent restenosis on death and myocardial infarction. Am J Cardiol 2007;100:1109-13.
79. Stone GW. Transcatheter cardiovascular therapeutics. 18th Annual Scientific Symposium; October 22-27, 2006; Washington, DC.